Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.
W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).
Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.
Bishoy M. Faltas, MD, of Weill Cornell Medical College, discusses his team’s work using whole exome sequencing, which may have important implications for selecting patients for immunotherapeutic approaches (Abstract 354).
